about
Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expressionCancer stem cells in basic science and in translational oncology: can we translate into clinical application?The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsNilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft modelRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaReducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRACD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinIdentification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HEvaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.Neoplastic stem cells: current concepts and clinical perspectives.Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells.The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.CD52 is a molecular target in advanced systemic mastocytosis.Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemiaA new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
P50
Q24634555-3B907BE8-2265-41C4-B620-92B598DA8BA8Q28081844-D2BF203C-0EE0-4004-ACCF-4E2BF7A1561FQ28480417-931D1FB6-5250-41A7-B84E-ECA33146530BQ28480622-9A9E82B4-3EEA-4679-B0A2-879041F3BB7FQ29617201-3D09BEC2-E88E-4E2F-9CD2-943BAC7FE168Q33412532-6E9882CA-0E10-4105-8263-7406AC980E9CQ35114558-51BB31C5-92FE-43E6-A2D3-41DD17EEC74DQ35717808-C0BD979B-ADF2-4251-9701-E8CEC0EFFB6FQ36755221-0A25759D-5A36-4440-8809-7F09CD8020F7Q36926120-B8ECBA6F-B814-4355-951E-1F7C10BF2D4AQ37611613-E142F83A-39A6-42F0-A856-5F6A657E1AF5Q37662286-182E691B-6FFA-44A1-A349-1C0DEFDB9E17Q37698810-CAE5FB35-DBDD-4ADF-AE74-F415222D86F3Q37812862-97296ABF-B7FC-45D2-BF23-8FA3557EA39EQ38159035-3D3F412B-D90D-4A87-93CE-1D0ED495CF10Q38265115-74FC22D7-6F25-48FD-B888-557671070710Q38812117-135D6F8F-930B-4536-86E2-E0567979A06FQ38866094-53CE714A-5CF3-401B-B763-E4731AA0523FQ38998107-64E2BBD7-F0A4-4B67-A82F-C35A5D134A99Q39001575-9A37DBDB-331C-4992-A225-59DA78A041ECQ39010282-CC4C4BA9-994E-4773-998F-C395D4EE31F9Q39010730-F87EE85E-616E-49FF-94A8-ABA2FD23DA36Q39294830-17A8683B-B156-4952-8756-C2C073A250DEQ39348704-EC704245-8788-4AF4-9FAB-6FDE813FAD18Q39375748-51DDFA35-9637-4879-A2A8-D592C139A17DQ39448460-1612F701-B29A-4B57-BB66-358AA93192FDQ39606792-2830887C-12D3-469E-91BA-4A936B92C38FQ39608346-E95906EB-3512-4701-A155-B1026AF0F21AQ39629538-D6B78296-2377-4781-B7DC-57740971A5C0Q39692224-03222A63-2E78-407A-AE34-871F6A075CB2Q39795335-06FE7721-7FDB-4686-BCCC-B0300EDBEBA1Q39840908-D2896C7C-E313-4C81-8D7F-E879F6E86AE8Q42217439-A4D33444-C3A9-4893-BBCB-E4B2F652A3E6Q43248374-F69C1173-3AFC-4994-BF7F-38DBB7D9075CQ43278551-ACBBB54D-30F5-410B-A098-74CBC337342CQ46075079-0DD2C6B8-8BFA-472C-AADA-6F28FAD32136Q46818989-0220E5A4-89E1-4983-AD44-334C0094E615Q47117016-FBDC0511-FE20-4D0A-8245-A60495B5854DQ47653225-81BC7BB5-7DA7-49CB-8685-3617424EB43CQ48104415-1D87FFEA-C05F-4B6B-BDF3-32959C5D52AE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Harald Herrmann
@ast
Harald Herrmann
@en
Harald Herrmann
@es
Harald Herrmann
@nl
type
label
Harald Herrmann
@ast
Harald Herrmann
@en
Harald Herrmann
@es
Harald Herrmann
@nl
prefLabel
Harald Herrmann
@ast
Harald Herrmann
@en
Harald Herrmann
@es
Harald Herrmann
@nl
P106
P31
P496
0000-0002-5095-4641